Sage Journals: Discover world-class research

Free access

Review article

First published 2016-4

Obinutuzumab for relapsed or refractory indolent non-Hodgkin’s lymphomas

Ludovic Gabellier, Guillaume Cartron

Therapeutic Advances in Hematology

Retricted access

Research article

First published 2020-12

The effect of gemcitabine,dexamethasone,and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience

Hikmettullah Batgi, Alparslan Merdin, Mehmet Sinan Dal [...]

Journal of Oncology Pharmacy Practice

Retricted access

Research article

First published 2012-11

Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Paul C. Kruger, Julian P. Cooney, J. Harvey Turner

Cancer Biotherapy and Radiopharmaceuticals

Open access

Research article

First published 2020

Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis

Jianhong Wang, Xiaohui Duan, Lijie Yang [...]

Cell Transplantation

Retricted access

Research article

First published 2003-08

131 I-Anti CD20 Radioimmunotherapy of Relapsed or Refractory Non-Hodgkins Lymphoma: A Phase II Clinical Trial of a Nonmyeloablative Dose Regimen of Chimeric Rituximab Radiolabeled in a Hospital

J. Harvey Turner, Andrew A. Martindale, Jan Boucek [...]

Cancer Biotherapy and Radiopharmaceuticals

Open access

Research article

First published 2025

Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia

Jean-Marie Michot, Zsofia Balogh, Jennifer R. Brown [...]

Therapeutic Advances in Drug Safety

Retricted access

Research article

First published 2013-06

Phase I Study of a Modified Regimen of 90 Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma

Christos Vaklavas, Ruby F. Meredith, Sui Shen [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2005-04

Yttrium-90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ® ) Induces Long-Term Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Gregory A. Wiseman, Thomas E. Witzig

Cancer Biotherapy and Radiopharmaceuticals

Open access

Research article

First published 2021-10

227 Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human,Phase I Study

Ola Lindén, Andrew T. Bates, David Cunningham [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2004-08

Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade,Follicular,or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia

Russell Schilder, Arturo Molina, Nancy Bartlett [...]

Cancer Biotherapy and Radiopharmaceuticals

Search results